DX

Diaceutics PLCLSE Diaceutics Stock Report

Last reporting period 30 Jun, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

0.15

Micro

Exchange

XLON - London Stock Exchange

DXRX.L Stock Analysis

DX

Uncovered

Diaceutics PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

15/100

Low score

Market cap $B

0.15

Dividend yield

Shares outstanding

84.339 B

Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland and currently employs 123 full-time employees. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training & educational resources. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX The Diagnostic Network. Its DXRX Data solutions provides unrivalled access to multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Its DXRX implementation services uses a range of industry service providers in precision medicine diagnostics to execute development and commercialization strategies at local level.

View Section: Eyestock Rating